Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

Sergio Leonardi, Pierluigi Tricoci, Harvey White, Paul Armstrong, Zhen Huang, Lars Wallentin, Philip Aylward, David Moliterno, F Van De Werf, Edmond Chen, Luis Providencia, Jan Nordrehaug, Claes Held, John Strony, Tyrus Rorick, Robert Harrington, Kenneth Mahaffey

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    AimsThe TRA·CER trial compared vorapaxar, a novel platelet protease-activated receptor (PAR)-1 antagonist, with placebo in 12 944 patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS). In this analysis, we explored the effect of vorapaxar on myocardial infarction (MI).Methods and resultsA blinded, independent central endpoint adjudication committee prospectively defined and classified MI according to the universal MI definition, including peak cardiac marker value (creatine kinase-MB [CK-MB] and/or troponin). Because the trial failed to meet its primary endpoint, these analyses are considered exploratory. During a median follow-up of 502 days, 1580 MIs occurred in 1319 patients. The majority (n = 1025, 64.9%) were type 1 (spontaneous) MI, followed by type 4a [percutaneous coronary intervention (PCI)-related] MI (n = 352; 22.3%). Compared with placebo, vorapaxar reduced the hazard of a first MI of any type by 12% [hazard ratio (HR), 0.88; 95% confidence interval (CI), 0.79-0.98; P = 0.021] and the hazard of total number of MIs (first and subsequent) by 14% (HR, 0.86; 95% CI, 0.77-0.97; P = 0.014), an effect that was sustained over time. Vorapaxar reduced type 1 MI by 17% (HR, 0.83; 95% CI, 0.73-0.95; P = 0.007). Type 4a MIs were not significantly reduced by vorapaxar (HR, 0.90; 95% CI, 0.73-1.12; P = 0.35). Vorapaxar effect was consistent across MI sizes defined by peak cardiac marker elevations and across key clinical subgroups; however, in patients not treated with thienopyridine at baseline (HR, 0.65; 95% CI, 0.46-0.92) compared with patients who received thienopyridine (HR, 0.91; 95% CI, 0.81-1.02), there was a trend towards a higher effect (Pint = 0.077).ConclusionThe PAR-1 antagonist vorapaxar was associated with a reduction of MI, including total number of infarctions. This reduction was sustained over time and was mostly evident in type 1 MI, the most common type of MI observed.

    Original languageEnglish
    Pages (from-to)1723-1731
    Number of pages9
    JournalEuropean Heart Journal
    Volume34
    Issue number23
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial'. Together they form a unique fingerprint.

  • Cite this

    Leonardi, S., Tricoci, P., White, H., Armstrong, P., Huang, Z., Wallentin, L., Aylward, P., Moliterno, D., Van De Werf, F., Chen, E., Providencia, L., Nordrehaug, J., Held, C., Strony, J., Rorick, T., Harrington, R., & Mahaffey, K. (2013). Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. European Heart Journal, 34(23), 1723-1731. https://doi.org/10.1093/eurheartj/eht104